Furthermore, to suggest potential new strategies for the treatment of HCC, we conducted a drug correlation analysis between signature genes and drugs and then found that the drug sensitivity of oxaliplatin and LDK-378 was negatively correlated with ITGAV expression. This evidence concerns the gene ITGAV and hepatocellular carcinoma.